PL369108A1 - Inhibitory dehydrogenazy 17 beta-hydroksysteroidowej typu 3 do leczenia chorób zależnych od androgenu - Google Patents
Inhibitory dehydrogenazy 17 beta-hydroksysteroidowej typu 3 do leczenia chorób zależnych od androgenuInfo
- Publication number
- PL369108A1 PL369108A1 PL02369108A PL36910802A PL369108A1 PL 369108 A1 PL369108 A1 PL 369108A1 PL 02369108 A PL02369108 A PL 02369108A PL 36910802 A PL36910802 A PL 36910802A PL 369108 A1 PL369108 A1 PL 369108A1
- Authority
- PL
- Poland
- Prior art keywords
- 17beta
- inhibitors
- treatment
- hydroxysteroid dehydrogenase
- dependent diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31771501P | 2001-09-06 | 2001-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL369108A1 true PL369108A1 (pl) | 2005-04-18 |
Family
ID=23234950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL02369108A PL369108A1 (pl) | 2001-09-06 | 2002-09-05 | Inhibitory dehydrogenazy 17 beta-hydroksysteroidowej typu 3 do leczenia chorób zależnych od androgenu |
Country Status (30)
Country | Link |
---|---|
US (3) | US6903102B2 (pl) |
EP (1) | EP1423381B1 (pl) |
JP (1) | JP4320252B2 (pl) |
KR (1) | KR100991616B1 (pl) |
CN (1) | CN1551878B (pl) |
AR (1) | AR036492A1 (pl) |
AT (1) | ATE350375T1 (pl) |
AU (1) | AU2002326823B2 (pl) |
BR (1) | BR0212378A (pl) |
CA (1) | CA2459311C (pl) |
CY (1) | CY1106521T1 (pl) |
DE (1) | DE60217363T2 (pl) |
DK (1) | DK1423381T3 (pl) |
EC (1) | ECSP045004A (pl) |
ES (1) | ES2276950T3 (pl) |
HK (1) | HK1062677A1 (pl) |
HU (1) | HUP0402629A3 (pl) |
IL (2) | IL160065A0 (pl) |
MX (1) | MXPA04002167A (pl) |
MY (1) | MY141661A (pl) |
NO (1) | NO327254B1 (pl) |
NZ (1) | NZ530810A (pl) |
PE (1) | PE20030703A1 (pl) |
PL (1) | PL369108A1 (pl) |
PT (1) | PT1423381E (pl) |
RU (1) | RU2315763C2 (pl) |
SI (1) | SI1423381T1 (pl) |
TW (1) | TWI329108B (pl) |
WO (1) | WO2003022835A1 (pl) |
ZA (1) | ZA200401456B (pl) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU756699B2 (en) | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
US6969718B2 (en) * | 2001-10-17 | 2005-11-29 | Schering Corporation | 17-β hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
JP4791183B2 (ja) | 2002-08-23 | 2011-10-12 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロン、その中間体、類似体の合成およびその使用 |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7132539B2 (en) | 2002-10-23 | 2006-11-07 | The Procter & Gamble Company | Melanocortin receptor ligands |
AU2003290799A1 (en) | 2002-11-18 | 2004-06-15 | Schering Corporation | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
MXPA05006485A (es) * | 2002-12-17 | 2005-08-26 | Schering Corp | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgeno. |
US7465739B2 (en) | 2003-06-10 | 2008-12-16 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
US7524853B2 (en) | 2003-06-10 | 2009-04-28 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
US7754709B2 (en) * | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
AR046901A1 (es) * | 2003-12-17 | 2005-12-28 | Schering Corp | Composiciones farmaceuticas |
WO2005066194A1 (en) | 2004-01-07 | 2005-07-21 | Endorecherche, Inc. | Helix 12 directed steroidal pharmaceutical products |
US7138246B2 (en) * | 2004-03-01 | 2006-11-21 | Bristol-Myers Squibb Company | Methods for identifying or screening for agents that modulate 17β-HSD3 |
US7417040B2 (en) | 2004-03-01 | 2008-08-26 | Bristol-Myers Squibb Company | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
US7569725B2 (en) | 2004-10-21 | 2009-08-04 | Britsol-Myers Squibb Company | Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
US7615556B2 (en) | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
US8884061B2 (en) * | 2006-03-03 | 2014-11-11 | Colorado State University Research Foundation | Compositions and methods of use of electron transport system inhibitors |
PT2029529E (pt) * | 2006-04-24 | 2010-09-02 | Lilly Co Eli | Pirrolidinonas substituídas como inibidores de 11 betahidroxiesteróide desidrogenase |
WO2007127704A1 (en) * | 2006-04-24 | 2007-11-08 | Eli Lilly And Company | Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
EP2565183A1 (en) | 2006-06-28 | 2013-03-06 | Amgen Inc. | Glycine transporter-1 inhibitors |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
US8080540B2 (en) * | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
EP2119709A4 (en) * | 2007-02-09 | 2011-08-17 | Kaneka Corp | PROCESS FOR PREPARING OPTICALLY ACTIVE 2-ARYLPIPERAZINE DERIVATIVE |
TWI433838B (zh) | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
US8501940B2 (en) * | 2008-07-15 | 2013-08-06 | Hoffmann-La Roche Inc. | Tetrahydrocinnoline derivatives |
US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
KR20140070550A (ko) | 2011-08-16 | 2014-06-10 | 마운트 시나이 스쿨 오브 메디슨 | 항암제로서의 삼환식 화합물 |
EP2961409A1 (en) * | 2013-02-26 | 2016-01-06 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
KR20160042873A (ko) | 2013-06-25 | 2016-04-20 | 포렌도 파마 리미티드 | 17.베타.-하이드록시스테로이드 탈수소효소의 억제제로서 치료적 활성 17-질소 치환된 에스트라트리엔티아졸 유도체 |
US10377791B2 (en) | 2013-06-25 | 2019-08-13 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 |
US9850272B2 (en) | 2013-06-25 | 2017-12-26 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1 |
CA2923884A1 (en) * | 2013-09-12 | 2015-03-19 | Pfizer Inc. | Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris |
CN103755626A (zh) * | 2014-01-23 | 2014-04-30 | 安徽安腾药业有限责任公司 | 一种贝托斯汀关键中间体的合成方法 |
FR3017868A1 (fr) * | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CN107207561B (zh) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
JP6545266B2 (ja) | 2014-12-23 | 2019-07-17 | フォレンド ファーマ リミテッド | 17β‐HSD1抑制剤のプロドラッグ |
US20210084900A1 (en) | 2017-05-04 | 2021-03-25 | Basf Se | Substituted 5-(haloalkyl)-5-hydroxy-isoxazoles for Combating Phytopathogenic Fungi |
CN110945007B (zh) | 2017-06-08 | 2022-11-18 | 佛恩多制药有限公司 | 用于抑制17β-羟基类固醇脱氢酶的15β-[3-丙酰氨基]-取代的雌-1,3,5(10)-三烯-17-酮化合物及其17-肟 |
CN113412269A (zh) | 2018-12-05 | 2021-09-17 | 佛恩多制药有限公司 | 作为17-hsd1抑制剂的在位置16(17)具有缩合的吡唑环的雌甾-1,3,5(10)-三烯化合物 |
US11957687B2 (en) | 2019-07-02 | 2024-04-16 | Regeneron Pharmaceuticals, Inc. | Modulators of HSD17B13 and methods of use thereof |
MX2022002282A (es) | 2019-08-28 | 2022-03-25 | Unilever Ip Holdings B V | Compuestos novedosos para aclarar la piel. |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3590389T1 (de) | 1984-08-02 | 1986-08-28 | Schering Corp., Kenilworth, N.J. | Pharmazeutische Zusammensetzung für eine Kombinationstherapie hormon-abhängiger Cancer |
IE62715B1 (en) | 1989-03-10 | 1995-02-22 | Endorecherche Inc | Combination therapy for treatment of estrogen sensitive diseases |
ATE269066T1 (de) | 1989-07-07 | 2004-07-15 | Endorech Inc | Kombinationstherapie zur prophylaxe und/oder behandlung von gutartiger prostatischer hyperplasie |
DE69034035T2 (de) | 1989-07-07 | 2004-01-22 | Endorecherche Inc., Ste-Foy | Methode zur behandlung androgenbedingter krankheiten |
JP2651043B2 (ja) * | 1990-07-10 | 1997-09-10 | 麒麟麦酒株式会社 | ジフェニルメチルピペラジン誘導体 |
IL99320A (en) | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical preparations containing them |
EP0553191B1 (en) * | 1990-10-10 | 1995-05-17 | Schering Corporation | Pyridine and pyridine n-oxide derivatives of diarylmethyl- piperidines or piperazines, compositions and use thereof |
US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
ES2089815T3 (es) | 1992-03-27 | 1996-10-01 | Schering Corp | Derivados de bis-aril-carbinol sin enlaces de puente, composiciones y metodos de uso. |
AU678409B2 (en) | 1992-10-28 | 1997-05-29 | Merck Sharp & Dohme Limited | 4-arylmethyloxymethyl piperidines as tachykinin antagonists |
AU682838B2 (en) | 1992-12-14 | 1997-10-23 | Merck Sharp & Dohme Limited | 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists |
EP0650495B1 (en) | 1993-05-17 | 2000-11-08 | Endorecherche Inc. | Improved antiandrogens |
CA2163995A1 (en) | 1993-06-07 | 1994-12-22 | Malcolm Maccoss | Spiro-substituted azacycles as neurokinin antagonists |
ATE170174T1 (de) | 1994-01-13 | 1998-09-15 | Merck Sharp & Dohme | Gem-bissubstituierte azazyclische tachykinin- antagonisten |
US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
US5719156A (en) | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5688960A (en) | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
US5654316A (en) | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
US5789422A (en) | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
US5968929A (en) | 1996-10-30 | 1999-10-19 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5945428A (en) | 1996-11-01 | 1999-08-31 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
US5783579A (en) | 1996-12-20 | 1998-07-21 | Schering Corporation | Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists |
AU754529B2 (en) * | 1998-09-22 | 2002-11-21 | Yamanouchi Pharmaceutical Co., Ltd. | Cyanophenyl derivatives |
US6063926A (en) | 1998-11-18 | 2000-05-16 | Schering Corporation | Substituted oximes as neurokinin antagonists |
US6204265B1 (en) | 1998-12-23 | 2001-03-20 | Schering Corporation | Substituted oximes and hydrazones as neurokinin antagonists |
DE60018707T2 (de) | 1999-01-25 | 2006-02-09 | Smithkline Beecham Corp. | Anti-androgene und verfahren zur behandlung von krankheiten |
US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
KR20020073586A (ko) | 2000-02-11 | 2002-09-27 | 버텍스 파마슈티칼스 인코포레이티드 | 피페라진 및 피페리딘 유도체 |
-
2002
- 2002-09-05 MY MYPI20023327A patent/MY141661A/en unknown
- 2002-09-05 DE DE60217363T patent/DE60217363T2/de not_active Expired - Lifetime
- 2002-09-05 CN CN028172507A patent/CN1551878B/zh not_active Expired - Fee Related
- 2002-09-05 BR BR0212378-9A patent/BR0212378A/pt not_active IP Right Cessation
- 2002-09-05 MX MXPA04002167A patent/MXPA04002167A/es active IP Right Grant
- 2002-09-05 EP EP02761567A patent/EP1423381B1/en not_active Expired - Lifetime
- 2002-09-05 AU AU2002326823A patent/AU2002326823B2/en not_active Ceased
- 2002-09-05 HU HU0402629A patent/HUP0402629A3/hu unknown
- 2002-09-05 NZ NZ530810A patent/NZ530810A/en not_active IP Right Cessation
- 2002-09-05 WO PCT/US2002/028181 patent/WO2003022835A1/en active Search and Examination
- 2002-09-05 ES ES02761567T patent/ES2276950T3/es not_active Expired - Lifetime
- 2002-09-05 PL PL02369108A patent/PL369108A1/pl not_active Application Discontinuation
- 2002-09-05 TW TW091120285A patent/TWI329108B/zh active
- 2002-09-05 PT PT02761567T patent/PT1423381E/pt unknown
- 2002-09-05 IL IL16006502A patent/IL160065A0/xx unknown
- 2002-09-05 JP JP2003526910A patent/JP4320252B2/ja not_active Expired - Fee Related
- 2002-09-05 US US10/235,627 patent/US6903102B2/en not_active Expired - Fee Related
- 2002-09-05 AR ARP020103351A patent/AR036492A1/es unknown
- 2002-09-05 DK DK02761567T patent/DK1423381T3/da active
- 2002-09-05 SI SI200230475T patent/SI1423381T1/sl unknown
- 2002-09-05 PE PE2002000878A patent/PE20030703A1/es not_active Application Discontinuation
- 2002-09-05 AT AT02761567T patent/ATE350375T1/de active
- 2002-09-05 RU RU2004110410/04A patent/RU2315763C2/ru not_active IP Right Cessation
- 2002-09-05 KR KR1020047003247A patent/KR100991616B1/ko not_active IP Right Cessation
- 2002-09-05 CA CA2459311A patent/CA2459311C/en not_active Expired - Fee Related
-
2004
- 2004-01-26 IL IL160065A patent/IL160065A/en not_active IP Right Cessation
- 2004-02-23 ZA ZA200401456A patent/ZA200401456B/en unknown
- 2004-03-04 EC EC2004005004A patent/ECSP045004A/es unknown
- 2004-04-05 NO NO20041452A patent/NO327254B1/no not_active IP Right Cessation
- 2004-06-09 HK HK04104134A patent/HK1062677A1/xx not_active IP Right Cessation
-
2005
- 2005-01-28 US US11/045,967 patent/US7138396B2/en not_active Expired - Fee Related
- 2005-11-14 US US11/273,712 patent/US7432268B2/en not_active Expired - Fee Related
-
2007
- 2007-03-16 CY CY20071100371T patent/CY1106521T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
EP1562897A4 (en) | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER | |
JO2372B1 (en) | Source drugs of 4-phenylpyridine derivatives | |
MY148480A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
WO2001081310A8 (en) | 1-aroyl-piperidinyl benzamidines | |
RS99203A (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
MXPA04004842A (es) | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. | |
MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
GB0112348D0 (en) | Compounds | |
HK1074592A1 (en) | 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
MXPA04003611A (es) | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
AP2003002929A0 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
MY135218A (en) | 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases | |
IL184116A0 (en) | Use of thiazolidinone derivatives as antiangiogenic agents | |
YU87202A (sh) | Derivati arilmetilamina koji se koriste kao inhibitori triptaze | |
BR0113389A (pt) | Compostos que inibem a atividade do fator xa | |
RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
MY130792A (en) | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | |
WO2001081316A3 (en) | Substituted phenyl farnesyltransferase inhibitors | |
MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments | |
RS44304A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
BRPI0513549A (pt) | composições farmacêuticas para o tratamento de leishmaniose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |